Vitrolife AB Interim report Q3, 2024: Improved growth with solid margins
Vitrolife reported strong Q3 2024 performance with sales reaching SEK 867 million, showing a 7% increase in local currencies. The company saw regional growth of 9% in EMEA, 2% in Americas, and 9% in APAC. Business areas showed varied performance with Consumables up 13%, Technologies up 11%, while Genetics remained flat. The gross margin improved to 58.6% from 55.7%. EBITDA reached SEK 289 million with a 33.4% margin. For the first nine months, total sales were SEK 2,650 million, with a 4% increase in local currencies and improved EBITDA of SEK 888 million.
Vitrolife ha riportato ottimi risultati per il terzo trimestre del 2024, con vendite che hanno raggiunto SEK 867 milioni, mostrando un aumento del 7% nelle valute locali. L'azienda ha visto una crescita regionale del 9% in EMEA, del 2% nelle Americhe e del 9% in APAC. Le aree di business hanno mostrato performance variegate, con i Consumabili in aumento del 13%, le Tecnologie in crescita dell'11%, mentre la Genetica è rimasta stabile. Il margine lordo è migliorato al 58.6% rispetto al 55.7%. L'EBITDA ha raggiunto SEK 289 milioni con un margine del 33.4%. Nei primi nove mesi, le vendite totali sono state di SEK 2,650 milioni, con un aumento del 4% nelle valute locali e un EBITDA migliorato di SEK 888 milioni.
Vitrolife reportó un sólido desempeño en el tercer trimestre de 2024, con ventas que alcanzaron SEK 867 millones, mostrando un aumento del 7% en monedas locales. La compañía vio un crecimiento regional del 9% en EMEA, del 2% en América y del 9% en APAC. Las áreas de negocio mostraron un rendimiento variado, con Consumibles en aumento del 13%, Tecnologías con un incremento del 11%, mientras que Genética permaneció estable. El margen bruto mejoró al 58.6% desde el 55.7%. El EBITDA alcanzó SEK 289 millones con un margen del 33.4%. En los primeros nueve meses, las ventas totales fueron de SEK 2,650 millones, con un aumento del 4% en monedas locales y un EBITDA mejorado de SEK 888 millones.
Vitrolife는 2024년 3분기 실적이 뛰어나며, 매출이 SEK 867백만에 달하고, 현지 통화에서 7% 증가했다고 보고했습니다. 회사는 EMEA에서 9%, 아메리카에서 2%, APAC에서 9%의 지역 성장을 보였습니다. 사업 분야별 성과는 차이를 보였으며, 소모품은 13% 증가, 기술은 11% 증가, 유전학은 변화가 없었습니다. 총 이익률은 55.7%에서 58.6%으로 개선되었습니다. EBITDA는 SEK 289백만에 도달하며 33.4%의 마진을 기록했습니다. 첫 아홉 개월 동안 총 매출은 SEK 2,650백만였으며, 현지 통화에서 4% 증가하고 EBITDA는 SEK 888백만으로 개선되었습니다.
Vitrolife a rapporté de bons résultats pour le troisième trimestre 2024, avec des ventes atteignant SEK 867 millions, affichant une augmentation de 7% dans les devises locales. L'entreprise a constaté une croissance régionale de 9% en EMEA, de 2% en Amériques et de 9% en APAC. Les domaines d'activité ont montré des performances variées, avec les Consommables en hausse de 13%, les Technologies en augmentation de 11%, tandis que la Génétique est restée stable. La marge brute s'est améliorée à 58.6% contre 55.7%. L'EBITDA a atteint SEK 289 millions avec une marge de 33.4%. Pour les neuf premiers mois, les ventes totales se sont élevées à SEK 2,650 millions, avec une augmentation de 4% dans les devises locales et un EBITDA amélioré de SEK 888 millions.
Vitrolife berichtete über eine starke Leistung im dritten Quartal 2024, mit einem Umsatz von SEK 867 Millionen, was einem Anstieg von 7% in lokalen Währungen entspricht. Das Unternehmen verzeichnete regionales Wachstum von 9% in EMEA, 2% in den Amerikas und 9% in APAC. Die Geschäftsbereiche zeigten unterschiedliche Leistungen, mit einem Anstieg der Verbrauchsmaterialien um 13%, Technologien um 11%, während die Genetik stabil blieb. Die Bruttomarge verbesserte sich auf 58.6% von 55.7%. Der EBITDA erreichte SEK 289 Millionen mit einer Marge von 33.4%. In den ersten neun Monaten betrugen die Gesamterlöse SEK 2,650 Millionen, mit einem Anstieg von 4% in lokalen Währungen und einem verbesserten EBITDA von SEK 888 Millionen.
- Sales increased 7% in local currencies to SEK 867 million in Q3
- Gross margin improved to 58.6% from 55.7% in Q3
- Strong regional growth in EMEA and APAC (both +9%)
- Consumables and Technologies segments showed double-digit growth (13% and 11%)
- Nine-month EBITDA increased to SEK 888 million with improved margin of 33.5%
- Earnings per share for nine months improved to SEK 2.76 from SEK 2.42
- Operating cash flow decreased to SEK 206 million from SEK 214 million in Q3
- Q3 net income declined to SEK 116 million from SEK 122 million
- Genetics business segment showed 0% growth in Q3
- Americas region showed weak growth of only 2% in Q3
Third quarter
- Sales of
SEK 867 (848) million, an increase of7% in local currencies and2% in SEK.
- Sales per region, in local currencies was +
9% in EMEA, +2% inAmericas and +9% in APAC.
- Sales per business area, in local currencies was +
13% in Consumables, +11% in Technologies and0% in Genetics.
- Gross margin increased to
58.6% (55.7).
- Operating income before depreciation and amortisation (EBITDA) was
SEK 289 (287) million, giving an EBITDA margin of33.4% (33.9).
- Operating cash flow decreased to
SEK 206 million (214).
- Net income was
SEK 116 (122) million, resulting in earnings per share ofSEK 0.85 (0.90).
First nine months
- Sales of
SEK 2,650 (2,607) million, an increase of4% in local currencies and2% in SEK.
- Sales per region, in local currencies was +
6% in EMEA, -2% inAmericas and +7% in APAC.
- Sales per business area, in local currencies was +
10% in Consumables, +20% in Technologies and -7% in Genetics.
- Gross margin increased to
58.6% (56.1).
- Operating income before depreciation and amortisation (EBITDA) increased to
SEK 888 (842) million, giving an EBITDA margin of33.5% (32.3).
- Operating cash flow increased to
SEK 640 million (586).
- Net income was
SEK 375 (328) million, resulting in earnings per share ofSEK 2.76 (2.42).
VITROLIFE AB (publ)
Bronwyn Brophy O´Connor, CEO
The information was submitted for publication, through the agency of the contact persons set out above, at 24-10-2024 08:00 CET.
Contact:
Patrik Tolf, CFO, phone +46 (0) 31 766 90 21
This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Interim report Q3, 2024 |
View original content:https://www.prnewswire.com/news-releases/vitrolife-ab-interim-report-q3-2024-improved-growth-with-solid-margins-302285557.html
SOURCE Vitrolife AB
FAQ
What was Vitrolife's (VTRLY) Q3 2024 revenue growth?
What was Vitrolife's (VTRLY) gross margin in Q3 2024?
How did Vitrolife's (VTRLY) different business segments perform in Q3 2024?
What was Vitrolife's (VTRLY) earnings per share for the first nine months of 2024?
